Last reviewed · How we verify
Cynara Scolymus
At a glance
| Generic name | Cynara Scolymus |
|---|---|
| Sponsor | Stefan Fischli |
| Drug class | Nitrate Vasodilator [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Relief of occasional eye overexertion
Common side effects
Key clinical trials
- Synbiotic Supplement With Botanical Extracts for Gut Microbiota Balance in Irritable Bowel Syndrome (NA)
- Multidomain Interventions for Elderly Individuals in Residential Structures (NA)
- Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial (PHASE2)
- Food Supplementation With Eufortyn Colesterolo Plus for LDL Modulation in Subjects With Polygenic Hypercholesterolemia (NA)
- Artichoke and Bergamot Phytosome (NA)
- The Metabolic Effects of Cynara Supplementation in Overweight and Obese Class I Subjects With Newly Detected Impaired Fasting Glycaemia. (NA)
- Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption (NA)
- Cynara Scolymus Extract for Treatment of Diabetes Mellitus Type 2 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cynara Scolymus CI brief — competitive landscape report
- Cynara Scolymus updates RSS · CI watch RSS
- Stefan Fischli portfolio CI